Patents Examined by Khatol S Shahnan-Shah
  • Patent number: 11547751
    Abstract: Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens from Clostridium Perfringens as vaccines to prevent necrotic enteritis (NE).
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: January 10, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Roy Curtiss, III, Shifeng Wang
  • Patent number: 11535652
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: December 27, 2022
    Assignee: Wyeth LLC
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Maninder K. Sidhu, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint
  • Patent number: 11497805
    Abstract: The present invention relates to Toll-Like Receptor 2 (TLR2) agonists, in particular, to TLR2-activating lipoproteins, and more particularly to TLR2-activating lipopeptides derived from the bacteria Bordetella pertussis. The invention further extends to the use of said TLR2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases.
    Type: Grant
    Filed: February 9, 2019
    Date of Patent: November 15, 2022
    Assignee: The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth, Near Dublin
    Inventors: Kingston Mills, Aisling Dunne
  • Patent number: 11478497
    Abstract: Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or other agents, and said agents may be used to treat or prevent a disease or condition associated with the fungi and parasite. The agent may target Kog1 of TORC1, e.g., the agent may directly or indirectly inhibit Kog1 leading to aggregation of the TORC1 complex.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 25, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Andrew P. Capaldi, James E. Hughes Hallett
  • Patent number: 11466075
    Abstract: Antibody-based binding agents derived from human and camelid immunoglobulins are described, as well as strains of yeast engineered to secrete the binding agents, and methods of treating and preventing Clostridium difficile infections using the engineered strains of yeast. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 11, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: Hanping Feng, James Eugene Galen, Kevin Chen, Yixuan Zhu
  • Patent number: 11434264
    Abstract: Ultrasensitive and quantitative assays for detecting toxins of Clostridium difficile, which may involve digital ELISA, are provided. Also provided herein are differential detection assays that allow for distinguishing toxin B of highly virulent Clostridium difficile strains from toxin B of less virulent strains.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 6, 2022
    Assignees: Quanterix Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Nira Pollock, Ciaran Kelly, David C. Duffy, Linan Song, Mingwei Zhao
  • Patent number: 11422127
    Abstract: Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 23, 2022
    Assignee: ALBANY MEDICAL COLLEGE
    Inventors: Edmund J. Gosselin, Sudeep Kumar, David Nalin
  • Patent number: 11406696
    Abstract: The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 9, 2022
    Inventors: Christiane Marie-Paule Simone Jeanne Feron, Stefan Jochen Kemmler, Michael Thomas Kowarik, Julien Laurent Quebatte
  • Patent number: 11395494
    Abstract: In aspect, a ready-to-use liquid larvicide composition comprises, consists essentially of, or consists of Bacillus thuringiensis (Bt) fermentate, propionic acid, and water. In other aspects, a composition comprises a fragrance and/or oil, a surfactant, an aqueous medium, and a larvicide.
    Type: Grant
    Filed: November 18, 2017
    Date of Patent: July 26, 2022
    Inventor: Fernando Thome Kreutz
  • Patent number: 11389492
    Abstract: The invention pertains to the use of a probiotic and a beta-lactoglobulin-derived peptide in the manufacture of a product for use in inducing oral tolerance, and/or treatment, prevention or reducing the risk of allergy in a subject, in particular cow's milk protein allergy.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 19, 2022
    Assignee: N.V. NUTRICIA
    Inventors: Leon Matthieu Johannes Knippels, Johan Garssen
  • Patent number: 11344587
    Abstract: Provided is a method of improving urogenital health, including administering to a subject a composition including an effective amount of a Lactobacillus johnsonii strain deposited under the accession number of DSM 33288 or a metabolite thereof. The Lactobacillus johnsonii strain, which is a probiotic, and metabolites thereof inhibit the growth of common pathogenic bacteria and fungi causing genitourinary tract infections, thereby reducing the risk of genitourinary tract infections or alleviating symptoms thereof. Also provided is a composition for improving urogenital health which includes the Lactobacillus johnsonii strain.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: May 31, 2022
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Chu-Han Huang, Cheng-Yu Ho
  • Patent number: 11298381
    Abstract: The present invention discloses a composition comprising heat inactivated spores and/or comprising heat inactivated vegetative cells of probiotic bacteria Bacillus coagulans, and a process for preparing the same. The invention also discloses a method of modulating immune function in mammals by activating macrophages, using a composition comprising Bacillus coagulans in the form of live or heat inactivated spore and/or vegetative cells.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 12, 2022
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Furqan Ali, Sivakumar Arumugam, Shaheen Majeed, Lakshmi Mundkur, Anurag Pande
  • Patent number: 11285197
    Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 29, 2022
    Assignee: Johns Hopkins University
    Inventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
  • Patent number: 11253562
    Abstract: The present invention relates to a feed supplement or a food supplement which comprises a resin acid based composition comprising over 10% (w/w) resin acids for use in in the prevention of intestinal disorders. The invention further relates to a use of the feed supplement or the food supplement and a feed composition or a food composition comprising the feed supplement or the food supplement, respectively.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: February 22, 2022
    Assignees: Forchem Oy, Hankkija Oy
    Inventors: Mikko Rintola, Juha Orte, Juhani Vuorenmaa
  • Patent number: 11246893
    Abstract: Methods are described herein for generating beneficial compounds and/or materials such as bacteriocins that include contacting ‘challenger’ microbes with the ‘protagonist’ microorganisms. The challenger microbes do not directly manufacture the beneficial compounds and/or materials and instead stimulate the protagonist microorganisms to produce beneficial compounds and materials. The protagonist and/or challenger microorganisms can be administered to a subject so the beneficial compounds and/or materials can be made in vivo. Compositions and methods of using beneficial compounds and/or materials are also described herein.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 15, 2022
    Assignee: ISOThrive Inc.
    Inventors: Lee Madsen, II, Jack Oswald, Sarah Stanley, Yvonne Lorraine Kapila
  • Patent number: 11246880
    Abstract: Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or other agents, and said agents may be used to treat or prevent a disease or condition associated with the fungi and parasite. The agent may target Kog1 of TORC1, e.g., the agent may directly or indirectly inhibit Kog1 leading to aggregation of the TORC1 complex.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 15, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Andrew P. Capaldi, James E. Hughes Hallett
  • Patent number: 11249090
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 15, 2022
    Assignees: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE DE PARIS
    Inventors: Lars Rogge, Silvia Menegatti, Maxime Dougados, Elisabetta Bianchi
  • Patent number: 11230590
    Abstract: In one aspect, the present invention is directed to a method for preventing or treating necrotic enteritis by administering a hyperimmunized egg product obtained from an egg-producing animal to an avian. The hyperimmunized egg product may contain an antibody specific to an antigen selected from the group consisting of Clostridium perfringens ?-toxin, Clostridium perfringens elongation factor Tu (EF-Tu), Clostridium perfringens necrotic enteritis B-like (NetB) toxin, Clostridium perfringens Pyruvate: Ferredoxin oxidoreductase (PFO), and Eimeria tenella elongation factor 1-alpha.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 25, 2022
    Assignees: Arkion Life Sciences, LLC, United States of America, as Represented by the Secretary of Agriculture
    Inventors: Hyun S. Lillehoj, Earnest W. Porta, Samuel V. Walker, Leslie A. Confer, Ujvala Deepthi Gadde, Cyril Gay
  • Patent number: 11213577
    Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: January 4, 2022
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventor: Claudia Gravekamp
  • Patent number: 11207375
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 28, 2021
    Assignees: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley